Still on HCC, Michael Karin (La Jolla, USA) presented a novel substrate of caspase 2 promoting steatosis and nonalcoholic steatohepatitis progression, identifying in caspase 2 a new target to prevent and treat these diseases. Here, CASP2 is linked to steatosis.